PF-Atlas › Clinical Trials › NCT03312400

Low-Dose Danazol for the Treatment of Telomere Related Diseases

Danazol · Phase 2

Registry ID

NCT03312400

Phase

Phase 2

Status

Completed

Drug / intervention

Danazol

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Start

2018-02-08

About this trial

Danazol is evaluated in NCT03312400, a Phase 2 idiopathic pulmonary fibrosis study sponsored by National Heart, Lung, and Blood Institute (NHLBI). Current status: Completed.

View NCT03312400 on ClinicalTrials.gov →

Explore related

All Danazol trials All IPF trials

Related trials

Danazol — NCT01441037

Medical disclaimer. This page summarizes public trial data for NCT03312400 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.